MSACL 2019 US Abstract

Development of a Parallel Reaction Monitoring Workflow for Biomarker Verification in Chronic Kidney Disease

Angela Mc Ardle (1), Qin Fu (1), Irina Tchernyshyov (1) and Jennifer E Van Eyk (1)
(1) Cedars Sinai Medical Center, Los Angeles

Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704

Angela Mc Ardle (Presenter) Cedars Sinai Medical Center

Presenter Bio: I studied at Trinity College Dublin where I received a bachelor’s degree in Biochemistry and Immunology and a master’s degree in Neuroscience. I developed keen interest in inflammatory and autoimmune disorders and became aware of how biomarkers could be used to improve personalized medical care across a plethora of disorders. This motivated me to get involved in biomarker research and during my doctoral studies at University College Dublin I sought to identify biomarkers with clinical utility in inflammatory arthritis. Through this work I developed a steadfast interest in mass spectrometry-based proteomics which lead me to join the Van Eyk group at Cedars Sinai Medical Centre. My postdoctoral research is centered on using mass spectrometry to detect global proteomic changes in the context of coronary artery disease and chronic kidney disease.

Relevant Financial Disclosures (within past 24 months) Grant/Research Support National Institute for Diabetes and Digestive and Kidney Diseases Discussing Products? NO, presenter will NOT present educational content related to products/services of the ineligible company(ies) listed above. Conflict mitigation NOT REQUIRED.

The most common serum biomarker used to indicate progression of (chronic kidney disease) CKD is serum creatinine and its derivative, estimated GFR. Estimated GFR is a strong predictor of CKD progression with recent meta analyses showing consistency of association across a broad range of causes. However, it is not able to adequately discriminate between people who progress to kidney failure from those who will not progress. Our hypothesis is that in depth proteomic discovery could identify novel plasma biomarkers that could be useful for the prognosis of CKD and to monitor progression (severity) of CKD.